513 related articles for article (PubMed ID: 38068789)
21. Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease.
Lee HH; Lee HA; Kim EJ; Kim HY; Kim HC; Ahn SH; Lee H; Kim SU
Gut; 2024 Feb; 73(3):533-540. PubMed ID: 37907259
[TBL] [Abstract][Full Text] [Related]
22. Oxidative stress in metabolic dysfunction-associated steatotic liver disease (MASLD): How does the animal model resemble human disease?
Jakubek P; Kalinowski P; Karkucinska-Wieckowska A; Kaikini A; Simões ICM; Potes Y; Kruk B; Grajkowska W; Pinton P; Milkiewicz P; Grąt M; Pronicki M; Lebiedzinska-Arciszewska M; Krawczyk M; Wieckowski MR
FASEB J; 2024 Feb; 38(3):e23466. PubMed ID: 38318780
[TBL] [Abstract][Full Text] [Related]
23. Fatty Liver Index (FLI) is the best score to predict MASLD with 50% lower cut-off value in women than in men.
Crudele L; De Matteis C; Novielli F; Di Buduo E; Petruzzelli S; De Giorgi A; Antonica G; Berardi E; Moschetta A
Biol Sex Differ; 2024 May; 15(1):43. PubMed ID: 38760802
[TBL] [Abstract][Full Text] [Related]
24. Oxidative balance score was negatively associated with the risk of metabolic syndrome, metabolic syndrome severity, and all-cause mortality of patients with metabolic syndrome.
Xu Z; Lei X; Chu W; Weng L; Chen C; Ye R
Front Endocrinol (Lausanne); 2023; 14():1233145. PubMed ID: 38283746
[TBL] [Abstract][Full Text] [Related]
25. Lower creatinine to cystatin C ratio is associated with an increased risk of MASLD: A cross-sectional and prospective study of 368,634 UK Biobank participants.
Wang J; Zeng L; Hong C; Cui H; Wang W; Zhu H; Li Q; Li Y; Li R; He J; Zhu H; Liu L; Xiao L
Clin Endocrinol (Oxf); 2024 Feb; 100(2):116-123. PubMed ID: 38146598
[TBL] [Abstract][Full Text] [Related]
26. Higher oxidative balance scores are associated with lower nonalcoholic fatty liver disease and not with fibrosis in US adults.
Liu X; Wang Y; Liu X; Zeng B; Zhu B; Zhang Y; Zhuang Y; Zhang Y; Dai F
Nutr Metab Cardiovasc Dis; 2023 Dec; 33(12):2488-2496. PubMed ID: 37798234
[TBL] [Abstract][Full Text] [Related]
27. Sex difference in skeletal muscle mass in relation to metabolic dysfunction-associated steatotic liver disease: a propensity score matching study.
Son DH; Kwon YJ; Lee JH
J Nutr Health Aging; 2024 Jun; 28(6):100270. PubMed ID: 38833877
[TBL] [Abstract][Full Text] [Related]
28. The prevalence and predictors of metabolic dysfunction-associated steatotic liver disease and fibrosis/cirrhosis among adolescents/young adults.
Perumpail BJ; Manikat R; Wijarnpreecha K; Cholankeril G; Ahmed A; Kim D
J Pediatr Gastroenterol Nutr; 2024 Apr; ():. PubMed ID: 38623942
[TBL] [Abstract][Full Text] [Related]
29. Autophagy, Ferroptosis, Apoptosis and Pyroptosis in Metabolic Dysfunction-Associated Steatotic Liver Disease.
Zhao S; Guo Y; Yin X
Front Biosci (Landmark Ed); 2024 Jan; 29(1):30. PubMed ID: 38287834
[TBL] [Abstract][Full Text] [Related]
30. Adherence to a healthy lifestyle including sleep and sedentary behaviors and risk of metabolic dysfunction-associated steatotic liver disease in Chinese adults.
Zhang S; Huo Z; Borné Y; Meng G; Zhang Q; Liu L; Wu H; Gu Y; Sun S; Wang X; Zhou M; Jia Q; Song K; Ma L; Qi L; Niu K
Prev Med; 2024 Jul; 184():107971. PubMed ID: 38657685
[TBL] [Abstract][Full Text] [Related]
31. Increased visceral fat area to skeletal muscle mass ratio is positively associated with the risk of metabolic dysfunction-associated steatotic liver disease in a Chinese population.
Liu C; Li N; Sheng D; Shao Y; Qiu L; Shen C; Liu Z
Lipids Health Dis; 2024 Apr; 23(1):104. PubMed ID: 38616253
[TBL] [Abstract][Full Text] [Related]
32. Inflammatory markers as diagnostic and precision nutrition tools for metabolic dysfunction-associated steatotic liver disease: Results from the Fatty Liver in Obesity trial.
Mogna-Peláez P; Riezu-Boj JI; Milagro FI; Herrero JI; Elorz M; Benito-Boillos A; Tobaruela-Resola AL; Tur JA; Martínez JA; Abete I; Zulet MA
Clin Nutr; 2024 Jul; 43(7):1770-1781. PubMed ID: 38861890
[TBL] [Abstract][Full Text] [Related]
33. The impact of metabolic syndrome severity on racial and ethnic disparities in Metabolic Dysfunction-Associated Steatotic Liver Disease.
Elsaid MI; Bridges JFP; Mumtaz K; Li N; Sobotka L; Rustgi VK; Paskett ED
PLoS One; 2024; 19(3):e0299836. PubMed ID: 38489287
[TBL] [Abstract][Full Text] [Related]
34. The association between metabolic dysfunction-associated steatotic liver disease, cardiovascular and cerebrovascular diseases and the thickness of carotid plaque.
Huang Y; Wang Y; Xiao Z; Yao S; Tang Y; Zhou L; Wang Q; Xie Y; Zhang L; Zhou Y; Lu Y; Zhu W; Chen M
BMC Cardiovasc Disord; 2023 Nov; 23(1):554. PubMed ID: 37951879
[TBL] [Abstract][Full Text] [Related]
35. Association of oxidative balance score with chronic kidney disease: NHANES 1999-2018.
Wen H; Li X; Chen J; Li Y; Yang N; Tan N
Front Endocrinol (Lausanne); 2024; 15():1396465. PubMed ID: 38919480
[TBL] [Abstract][Full Text] [Related]
36. Machine learning identification of risk factors for heart failure in patients with diabetes mellitus with metabolic dysfunction associated steatotic liver disease (MASLD): the Silesia Diabetes-Heart Project.
Nabrdalik K; Kwiendacz H; Irlik K; Hendel M; Drożdż K; Wijata AM; Nalepa J; Janota O; Wójcik W; Gumprecht J; Lip GYH
Cardiovasc Diabetol; 2023 Nov; 22(1):318. PubMed ID: 37985994
[TBL] [Abstract][Full Text] [Related]
37. Circulating hormones in biopsy-proven steatotic liver disease and steatohepatitis: A Multicenter Observational Study.
Valenzuela-Vallejo L; Chrysafi P; Kouvari M; Guatibonza-Garcia V; Mylonakis SC; Katsarou A; Verrastro O; Markakis G; Eslam M; Papatheodoridis G; Mingrone G; George J; Mantzoros CS
Metabolism; 2023 Nov; 148():155694. PubMed ID: 37757973
[TBL] [Abstract][Full Text] [Related]
38. Inflammatory Bowel Disease Is an Independent Risk Factor for Metabolic Dysfunction-Associated Steatotic Liver Disease in Lean Individuals.
Martínez-Domínguez SJ; García-Mateo S; Gargallo-Puyuelo CJ; Gallego-Llera B; Callau P; Mendi C; Arroyo-Villarino MT; Simón-Marco MÁ; Ampuero J; Gomollón F
Inflamm Bowel Dis; 2023 Aug; ():. PubMed ID: 37607330
[TBL] [Abstract][Full Text] [Related]
39. Insulin resistance and central obesity determine hepatic steatosis and explain cardiovascular risk in steatotic liver disease.
Semmler G; Balcar L; Wernly S; Völkerer A; Semmler L; Hauptmann L; Wernly B; Aigner E; Niederseer D; Datz C
Front Endocrinol (Lausanne); 2023; 14():1244405. PubMed ID: 37842290
[TBL] [Abstract][Full Text] [Related]
40. Recent advances in age-related metabolic dysfunction-associated steatotic liver disease.
He QJ; Li YF; Zhao LT; Lin CT; Yu CY; Wang D
World J Gastroenterol; 2024 Feb; 30(7):652-662. PubMed ID: 38515956
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
